People with ANCA-associated vasculitis (AAV) have a significantly higher risk of developing certain blood and solid-organ cancers, compared with those without the rare autoimmune disease, according to a large real-world study in the U.S. The study examined the medical records of more than 18,000 people with AAV and a…
News
Dupilumab, an approved medication for diseases marked by high levels of the immune cell eosinophils, may help ease symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA), according to a study reporting on three patients. The therapy, sold as Dupixent, helped control asthma and atopic dermatitis — two conditions…
People with active granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), had significantly higher levels of a specific type of immune cell called peripheral helper T (Tph) cells in their blood, a study found. Higher levels of circulating Tph (cTph) cells were also significantly linked…
Amgen said it declined a U.S. Food and Drug Administration (FDA) request to voluntarily withdraw Tavneos (avacopan), an oral treatment approved for the most common forms of ANCA-associated vasculitis (AAV), from the U.S. market. The FDA made the request because of concerns about the integrity of clinical…
Children with ANCA-associated vasculitis (AAV) have higher numbers of two specific subsets of neutrophils, a type of immune cell implicated in AAV, that produce high levels of molecules linked to inflammation and other damaging processes, a small study showed. Notably, these overactive neutrophils appear to have difficulty processing glutamine,…
Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos (avacopan), an oral therapy approved for ANCA-associated vasculitis (AAV). In a press release, the European Medicines Agency (EMA) announced that it “will now review all available data to…
Rituximab is at least as effective as cyclophosphamide in inducing remission in people with ANCA-associated vasculitis (AAV), and it may offer a safer, more targeted option for many patients, according to a review study. “These findings reinforce the evolving role of rituximab…
Inflammation markers calculated from routine blood tests, such as ratios of different types of immune cells and a combined inflammation index, appear to increase when ANCA-associated vasculitis (AAV) is more active, a study found. Even though these markers are not specific to AAV, they “may serve as potential supportive…
A study linked high levels of a blood protein called CXCL6 with lung disease in people with ANCA-associated vasculitis (AAV), pointing to the protein as a potential biomarker to diagnose the condition and monitor its progression. Data indicate that people with AAV who have inflammatory lung disease tend to…
More than one-third of patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) already have serious heart disease, a study found. The research also identified coronary artery spasms, sudden episodes of tightening in the heart’s blood vessels that reduce blood flow and can mimic a heart attack, as…
Recent Posts
- What a hip replacement taught me about bone health and vasculitis
- Cancer risk 23% higher in people with AAV, large US study finds
- Asthma drug dupilumab may ease symptoms in EGPA: Small study
- A valentine for the people who show up in our lives with ANCA vasculitis
- Immune cell surge tied to inflammation and disease activity in active GPA